Acinetobacter infections, caused by bacteria of the Acinetobacter genus, pose a significant threat in healthcare settings, particularly among critically ill patients. These bacteria are known for their ability to survive on various surfaces and resist common disinfectants, contributing to their persistence in hospital environments. Acinetobacter baumannii is the most clinically relevant species within this genus and is associated with a range of infections, including pneumonia, bloodstream infections, and wound infections. Hospital-acquired Acinetobacter infections are often linked to invasive medical procedures, prolonged hospital stays, and the use of broad-spectrum antibiotics. The bacteria's inherent resistance to multiple antimicrobial agents, including carbapenems, poses a considerable challenge in treatment. Multidrug-resistant strains have emerged, necessitating a judicious and tailored approach to antibiotic therapy. Preventive measures, such as strict infection control practices and antimicrobial stewardship, are crucial in mitigating the spread of Acinetobacter infections within healthcare facilities. Ongoing research focuses on understanding the mechanisms of antibiotic resistance and developing novel therapeutic strategies to combat these resilient bacteria.